Targeted Liposomes Drug Delivery Companies

Pfizer and Acuitas Therapeutics enter a development and option agreement: This strategic partnership empowers Pfizer with a non-exclusive option to license Acuitas' lipid nanoparticle (LNP) technology for up to 10 targets, signifying Pfizer's commitment to innovative solutions in both vaccine and therapeutic development.

Alnylam Pharmaceuticals strengthens its LNP development capabilities: They acquire Viaceutics, a company specializing in high-throughput screening and formulation development for RNA interference (RNAi) therapeutics, aiming to accelerate discovery and delivery of their RNAi therapies.

Arrowhead Pharmaceuticals announces the first patient dosed in its Phase 1b/2a clinical trial for AROENVI (ARO-C04): This investigational siRNA therapy leverages Arrowhead's proprietary DuoHex2™ delivery platform to target ENPP3 for the treatment of non-alcoholic steatohepatitis (NASH).

Genmab and Roche unveil Mosquirix™ (tezepelumab): This first-in-class biologic, delivered via subcutaneous injection, utilizes a specifically designed monoclonal antibody targeted against IL-5 receptor α to control severe asthma.

• Catalent (US)


• Pacira Pharmaceuticals, Inc. (US)


• Baxter (US)


• Lonza (Switzerland)


• Evonik (Germany)


• Merck KGaA (Germany)


• Fareva (France)


• Vetter (Germany)


• Polymun Scientific Immunbiologische Forschung GmbH (Austria)


• Recipharm AB (Sweden)


• Dalton Pharma Services (Canada)